The biotechnology company signed an arrangement with Arena Pharmaceuticals, a medical-phase business, to get a total fairness valued at about $6.7 billion.
Pfizer will acquire all shares at $100 per share through an all-dollars deal, per the settlement, according to a press launch.
Arena Pharmaceuticals has a pipeline focused to cannabis-dependent therapeutics, with the Olorinab (APD371) at its main.
The Olorinab (APD371) is an oral, investigational, whole agonist for the hashish kind 2 receptor, according to Arena Prescription drugs.
The aim is to use the cure to deal with people with illnesses of the tummy and intestine, but it is not authorized for provider by any overall health authority, in accordance to a report.
“The proposed acquisition of Arena enhances our abilities and abilities in Irritation and Immunology, a Pfizer innovation motor establishing possible therapies for clients with debilitating immuno-inflammatory illnesses with a need for far more helpful treatment selections,” Mike Gladstone, world president of swelling and immunology at Pfizer, said in the push launch.
The deal is topic to all closing ailments, which include approval by Arena’s shareholders and regulatory approvals, the report noted.
Original Location: Pfizer enters healthcare marijuana marketplace with $6.7 billion hashish bet
Washington Examiner Video clips